BLINCYTO (blinatumomab), monoclonal antibody

ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 06 2016

Reason for request

Inclusion

Moderate improvement in the treatment of Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia

 

  • BLINCYTO has Marketing Authorisation in the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (Ph- B-ALL).
  • Its efficacy in terms of complete remission (CR) and complete remission with partial haematological recovery (CRh) has been demonstrated. A little less than half of patients (40%) who achieved remission had received an allogeneic stem cell transplant.
  • Clinical data are limited, pending the results of a comparative study.
  • This is a second-line and subsequent treatment for Ph- B-ALL.

 


Clinical Benefit

Substantial

-


Clinical Added Value

moderate

-


Therapeutic use

-

Contact Us

Évaluation des médicaments